A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT01297244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Study identification
- NCT ID
- NCT01297244
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- Tivozanib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Sep 30, 2012
- Completion
- Sep 30, 2012
- Last update posted
- Oct 26, 2020
2011 – 2012
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center | Mobile | Alabama | — | — |
| Providence Health and Services | Burbank | California | — | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | — | — |
| Rocky Mountain Cancer Center | Denver | Colorado | — | — |
| St. Francis Cancer Research Foundation | Beech Grove | Indiana | — | — |
| Cancer Center of Kansas | Wichita | Kansas | — | — |
| Medical Oncology, LLC | Baton Rouge | Louisiana | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Cancer & Hematology Centers of Western Michigan | Grand Rapids | Michigan | — | — |
| North Mississippi Hematology & Oncology Associates, Ltd. | Tupelo | Mississippi | — | — |
| Comprehensive Cancer Centers of Nevada & US Oncology Research | Las Vegas | Nevada | — | — |
| Mary Hitchcock Memorial Hospital, NH | Lebanon | New Hampshire | — | — |
| University of North Carolina, Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | — | — |
| Ohio State University | Columbus | Ohio | — | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | — | — |
| The Jones Clinic | Germantown | Tennessee | — | — |
| The West Clinic | Memphis | Tennessee | — | — |
| Texas Oncology-Austin North | Austin | Texas | — | — |
| Coastal Bend Cancer Center | Corpus Christi | Texas | 78404 | — |
| Texas Oncology-Baylor, Charles A. Sammons Cancer Center | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01297244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2020 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01297244 live on ClinicalTrials.gov.